T
THERAVECTYS
Biotech & Life Sciences · Paris, France · Founded 2005
THERAVECTYS develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions. MoreLess
Theravectys operates in the biotech sector, focusing on the development of T cell vaccines using a proprietary lentiviral vector platform. The company targets both prophylactic and therapeutic vaccines, addressing critical unmet medical needs such as chronic infections and cancers, including the global HIV epidemic. By leveraging over 20 years of research, Theravectys aims to transform the field of vaccinology through strategic industrial partnerships and collaborations, including a joint laboratory with the Pasteur Institute. The business model centers on preclinical proof of concept across a broad range of indications, moving products through clinical stages and regulatory approval. Revenue is generated through global licensing and partnerships, positioning Theravectys as a potential game-changer in global health. Keywords: lentiviral vectors, T cell vaccines, chronic infections, cancers, HIV, biotech, partnerships, clinical trials, global health, licensing.
Company overview
THERAVECTYS company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2005
- Headquarters
- Paris, France
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 69.0
Valuation & funding
THERAVECTYS funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Feb 2021 | $18M | $73M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Jan 2015 | $2.1M | $8.4M | Bpifrance | — |
| LATE VC✓Equity / VC | Oct 2013 | $16M | $65M | Undisclosed | — |
| EARLY VC✓Equity / VC | Sep 2012 | $8.2M | $33M | John PIETERS · Philippe ODDO | — |
| SPINOUT✓Other financing | Jan 2005 | $0 | — | Institut Pasteur | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
THERAVECTYS website traffic
Latest recorded traffic for THERAVECTYS is 2.3K monthly website visits, up 167.4% over the last three months. THERAVECTYS's team declined 15.8% over the past year.
Comparisons
THERAVECTYS compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
THERAVECTYS's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where THERAVECTYS has talent and traffic
team presence
In the news
Latest news about THERAVECTYS
Recent press, funding announcements, and product moves mentioning THERAVECTYS — open to read from the original sources.
Market sentiment
What the market is saying about THERAVECTYS
An AI-synthesized read of the highest-engagement posts about THERAVECTYS on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See THERAVECTYS’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.